Andere Sprachen NeuroSense Therapeutics Ltd.

Aktien

A3DFK1

IL0011809592

NRSN

Verzögert Nasdaq Andere Börsenplätze 16:48:19 17.05.2024			% 5 Tage	% 1. Jan.
1,2 ^USD	-1,64 %		+1,69 %	+52,87 %

14.05.	NeuroSense schließt Partnerschaft mit PhaseV für ALS-Behandlungsstudie -- Aktien steigen	MT
07.05.	NeuroSense gibt neue positive Datenanalyse aus der klinischen PARADIGM-Studie bekannt, die eine statistisch signifikante Verlangsamung des Krankheitsverlaufs bei ALS-Hochrisikopatienten zeigt	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

NeuroSense Partners with PhaseV for ALS Treatment Trial -- Shares Up	14.05.
NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning	14.05.
NeuroSense Therapeutics : Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning - Form 6-K	14.05.
NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients	07.05.
NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients	07.05.
NeuroSense to Collaborate With Genetika+ on Alzheimer's Disease Drug Development; Shares Fall	22.04.
NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease	22.04.
NeuroSense Therapeutics Ltd. and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease	22.04.
NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting	19.04.
NeuroSense Therapeutics Ltd. Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting	18.04.
NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024	15.04.
NeuroSense Therapeutics Prices $4.5 Million Offering of Ordinary Shares, Warrants	11.04.
NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement	11.04.
NeuroSense Therapeutics Ltd. announced that it expects to receive $4.47 million in funding	10.04.
NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics	09.04.
NeuroSense Therapeutics Ltd. Collaborates with Lonza to Identify Exosome-Based Biomarkers, in Order to Advance Neurodegenerative Disease Treatments and Diagnostics	09.04.
NeuroSense Announces Year End 2023 Financial Results and Provides Business Update	08.04.
NeuroSense Announces Year End 2023 Financial Results and Provides Business Update	05.04.
NeuroSense Therapeutics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04.04.
NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial	21.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen NeuroSense Therapeutics Ltd.

Aktien

A3DFK1

IL0011809592

NRSN

Andere Sprachen

Filter